Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
M Chalabi, LF Fanchi, KK Dijkstra, JG Van den Berg… - Nature medicine, 2020 - nature.com
Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …
Exploring immunotherapy in colorectal cancer
J Weng, S Li, Z Zhu, Q Liu, R Zhang, Y Yang… - Journal of hematology & …, 2022 - Springer
Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Tumor mutational burden as a predictor of immunotherapy response: is more always better?
Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
Advances in cancer immunotherapy 2019–latest trends
Immunotherapy has become an established pillar of cancer treatment improving the
prognosis of many patients with a broad variety of hematological and solid malignancies …
prognosis of many patients with a broad variety of hematological and solid malignancies …
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
P Zhao, L Li, X Jiang, Q Li - Journal of hematology & oncology, 2019 - Springer
Immunotherapies have led to substantial changes in cancer treatment and have been a
persistently popular topic in cancer research because they tremendously improve the …
persistently popular topic in cancer research because they tremendously improve the …
Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion
D Chakravarty, A Johnson, J Sklar… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …
membership following publication or presentation of potentially practice-changing data from …
[HTML][HTML] Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms …
DM Merino, LM McShane, D Fabrizio… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Tumor mutational burden (TMB), defined as the number of somatic mutations
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …